Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Kidney cancer
Zanzalintinib (VEGFR/MET) + Nivolumab Yields 63% ORR in Front-Line ccRCC; Triplet With Relatlimab Lags
Zanzalintinib (zanza; XL092) is an oral multi-kinase TKI targeting VEGFR, MET, and TAM receptors; in the Phase 1b STELLAR-002 expansion (NCT05176483), 40 untreated metastatic Clear Cell Renal Carcinoma (ccRCC)…
NCT05176483 - Trial result
Sarcoma and GIST
Epirubicin/Ifosfamide + Nivolumab Hits 69% ORR in First-Line Undifferentiated Pleomorphic Sarcoma
Epirubicin (anthracycline; 60 mg/m² d1-2) and ifosfamide (3 g/m² d1-3) paired with the PD-1 inhibitor nivolumab (360 mg d3) were tested in 3-week cycles in the Spanish phase Ib ImmunoSarc2 cohort 7a (NCT03277924).…
NCT03277924 - Trial result
Stomach and esophageal cancer
Zanidatamab (HER2 bispecific) + Chemo Drives 76% ORR and 36.5-mo OS in 1L HER2-Positive GEA
Zanidatamab, a dual-epitope HER2-targeted bispecific antibody, was added to CAPOX, FP, or mFOLFOX6 in the single-arm Phase 2 NCT03929666 trial across Canada, Korea, and the USA. Among 46 treatment-naïve,…
NCT03929666 - New trial
Non-small cell lung cancer
Phase 3 trial: Belrestotug (TIGIT mAb) plus Dostarlimab (PD-1 inhibitor) in PD-L1 high NSCLC.
This randomized, multicenter, double‑blind study compares belrestotug, a TIGIT monoclonal antibody, and dostarlimab, a PD‑1 inhibitor, versus pembrolizumab plus placebo for first‑line treatment of unresectable,…
NCT06472076 Registrational - New trial
Non-small cell lung cancer
Phase II trial of Zimberelimab, a PD-1 inhibitor, in advanced NSCLC immunotherapy combinations.
This open-label platform study evaluates objective response and safety of various immunotherapy regimens in advanced non-small cell lung cancer. Investigational arms pair zimberelimab (a PD-1 inhibitor) with…
NCT05676931 - New trial
Non-small cell lung cancer
Phase II trial of Fingolimod, a sphingosine‐1‐phosphate receptor modulator, in advanced NSCLC and SCLC.
This single-institution, open-label study evaluates daily oral fingolimod 0.5 mg in patients with advanced NSCLC or SCLC who have progressed on chemo-immunotherapy. A six-patient safety lead-in precedes expansion…
NCT06424067 Exploratory - New trial
Multiple solid tumors
Phase 1 trial of ZZ06, an EGFR mAb, in advanced EGFR-positive solid tumors.
This open-label, multicenter study determines the maximum tolerated dose and characterizes safety, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary antitumor activity of ZZ06 as a single agent in…
NCT04412616 First-in-human - New trial
Multiple solid tumors
Phase 1 study of ADCE-T02, a tissue factor targeted antibody-drug conjugate in advanced solid tumors.
This first-in-human, dose-escalation study evaluates ADCE-T02 as a single agent in patients with unresectable advanced solid tumors who have progressed on ≥2 lines of therapy. The trial aims to determine the maximum…
NCT06597721 First-in-human - New trial
Multiple solid tumors
Phase 1a/1b study of DR-0202, a Dectin-1 and CD20 bispecific mAb in refractory carcinomas.
This multicenter, open-label study evaluates the safety, tolerability, and activity of DR-0202 administered every two weeks in patients with advanced or metastatic, relapsed or refractory carcinomas who have…
NCT06999187 First-in-human - New trial
Pancreatic cancer
Phase I trial of emavusertib IRAK4/FLT3 inhibitor with gemcitabine and nab-paclitaxel
This Phase I study evaluates the safety and optimal dosing of emavusertib combined with gemcitabine and nab-paclitaxel in patients with metastatic or unresectable pancreatic ductal adenocarcinoma. Sponsored by the…
NCT05685602 - New trial
Colorectal cancer
Phase 2 Trial of CBX-12, a Topoisomerase I Inhibitor, for Metastatic Colorectal Cancer
This trial evaluates CBX-12 given as a 60-minute IV infusion every 21 days in patients with chemotherapy-refractory, microsatellite stable metastatic colorectal cancer. Eligible participants include those with…
NCT06730100 - New trial
Stomach and esophageal cancer
Phase III HLX22 HER2-targeted mAb trial in first-line gastric cancer
This randomized, double-blind phase III study evaluates HLX22 combined with trastuzumab and XELOX versus standard treatment with or without pembrolizumab for HER2-positive locally advanced or metastatic gastric and…
NCT06532006 Registrational - New trial
Uterine (endometrial) cancer
Phase 3 Sacituzumab Tirumotecan TROP2-directed ADC for Endometrial Cancer
This Phase 3 study evaluates whether sacituzumab tirumotecan combined with pembrolizumab prolongs survival and delays disease progression versus pembrolizumab alone in patients with advanced or recurrent mismatch…
NCT06952504 Registrational - New trial
Ovarian cancer
Phase 3 trial: Trastuzumab Deruxtecan, HER2-directed ADC with topoisomerase I inhibition.
This Phase 3 randomized, open-label trial by Daiichi Sankyo compares T‑DXd with bevacizumab combination therapy versus bevacizumab monotherapy as first-line maintenance for patients with stage 3/4 high-grade…
NCT06819007 Registrational - New trial
Liver and bile duct cancer
Phase I/II Trial: Sapanisertib (mTORC1/2 inhibitor) and cabozantinib in β-catenin–mutated metastatic liver cancer
This trial compares sapanisertib plus cabozantinib versus cabozantinib monotherapy, evaluating safety, dosing, and efficacy in metastatic hepatocellular carcinoma patients (including a β-catenin-mutated subgroup) to…
NCT06811116 - New trial
Head and neck cancer
Phase 2 Trial of Cisplatin, a DNA crosslinker, in dose-adjusted chemoradiation.
Investigating whether reduced-dose, smaller-field IMRT with weekly cisplatin maintains survival while lessening long-term toxicities compared to standard treatment, the trial enrolls elderly patients with p16+…
NCT06309225 - New trial
Brain and CNS tumors
Phase 2 trial of sitagliptin as a DPP-4 inhibitor for Grade 4 gliomas.
This study evaluates sitagliptin given before and after surgery in resectable Grade 4 glioma patients at Case Comprehensive Cancer Center in Cleveland. It is designed to assess if targeting MDSCs via DPP-4 inhibition…
NCT07003542 Exploratory - New trial
Prostate cancer
Phase 1 study of STM-416p, a resiquimod TLR7/8 activator
This study evaluates the safety and optimal dosing of intraoperative STM-416p in men with Grade group 2–5 prostate cancer undergoing radical prostatectomy. Conducted at Tucson and Gainesville sites, the trial is…
NCT06450106 First-in-human - New trial
Sarcoma and GIST
Phase II trial of pembrolizumab PD‑1 inhibitor in advanced cutaneous sarcoma
This single arm, open-label Phase II study evaluates pembrolizumab monotherapy given every 21 days in adult patients with advanced cutaneous sarcomas (excluding angiosarcoma). Sponsored by H. Lee Moffitt Cancer…
NCT07007273 - New trial
Other blood cancers and transplant
Phase I/II AZD9829: CD123-directed mAb Topo1 inhibitor ADC
This open-label, multicenter study assesses the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD9829 administered intravenously as monotherapy or in combination. It enrolls patients…
NCT06179511 First-in-human - Trial result
Non-small cell lung cancer
Sigvotatug vedotin (IB6 ADC) + pembrolizumab hits 57% ORR in PD-L1⁺ NSCLC
Sigvotatug vedotin, an integrin β6–directed vedotin ADC, was paired with pembrolizumab in the Phase 1 SGNB6A-001 escalation/expansion trial (NCT04389632). Thirty-one patients with advanced NSCLC (n = 19) or HNSCC (n…
NCT04389632 - Trial result
Non-small cell lung cancer
Datopotamab Deruxtecan (TROP2-ADC) + Pembrolizumab Delivers 55–56% ORR and 20-Month DoR in First-Line Advanced NSCLC
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody–drug conjugate, was paired with the PD-1 inhibitor pembrolizumab ± platinum chemotherapy in the Phase 1b/2 TROPION-Lung02 trial (NCT04526691). Among 96…
NCT04526691 - Trial result
Non-small cell lung cancer
ctDNA Sequencing Flags KEAP1, STK11 & NOTCH as Frequent Drivers of ICI Resistance in NSCLC
In a prospective two-cohort study (STING + COPE; n = 57) that collected plasma before therapy and at radiographic progression, investigators used an FDA-approved 500-gene ctDNA panel to profile resistance mechanisms…
NCT04932525 - Trial result
Non-small cell lung cancer
Taletrectinib Hits 89% ORR and 45.6-Month PFS in TKI-Naïve ROS1-Positive NSCLC
Taletrectinib, a next-generation ROS1/ALK tyrosine-kinase inhibitor designed to cover the G2032R resistance mutation and penetrate the CNS, was evaluated in the pooled Phase II TRUST-I/II program…
NCT04395677 - Trial result
Non-small cell lung cancer
Lorlatinib Depth of Response Tracks with 75% 5-Year PFS in First-Line ALK-Positive NSCLC
In the phase 3 CROWN trial (lorlatinib, a ALK inhibitor, n = 149 vs. crizotinib, an ALK and cMET TKI inhibitor, n = 147), 95% of lorlatinib-treated, treatment-naïve ALK-positive NSCLC patients were evaluable for…
- Trial result
Non-small cell lung cancer
Amivantamab + Carbo-Paclitaxel Halves Risk of Progression After Osimertinib—Regardless of EGFR or MET Resistance Mechanism
In the phase 3 MARIPOSA-2 trial (NCT04988295) of EGFR-mutant (Ex19del/L858R), which accounts for about 32% of all NSCLC cases%20in%20Europe.), advanced NSCLC patients that had progressed on osimertinib, 131 patients…
NCT04988295 - Trial result
Non-small cell lung cancer
Adagrasib + Pembrolizumab Posts 44% ORR and 26-Month DoR as Chemo-Free First-Line Option for KRAS-G12C NSCLC
In the Phase 2 KRYSTAL-7 study (NCT04613596), 149 untreated metastatic KRAS-G12C NSCLC patients received adagrasib (KRAS G12C inhibitor) 400 mg BID plus pembrolizumab (PD-1 checkpoint inhibitor) Q3W. About 13% of…
NCT04613596 - Trial result
Non-small cell lung cancer
Olomorasib + Pembrolizumab Delivers 70% ORR and 80% 6-mo PFS in Front-Line KRAS-G12C NSCLC
Olomorasib (LY3537982), a next-generation covalent KRAS-G12C inhibitor, was combined with pembrolizumab (PD-1 checkpoint inhibitor) in the Phase 1/2 LOXO-RAS-20001 trial (NCT04956640). 43 previously untreated…
NCT04956640 - Trial result
Non-small cell lung cancer
Teliso-V ctDNA Study Finds 100% ORR in KRAS-G12C and Better Survival When Baseline ctDNA Is Low
In the LUMINOSITY stage-2 analysis, 83 previously treated, EGFR-wild-type, c-Met-overexpressing NSCLC patients received telisotuzumab vedotin, an ADC targeting c-MET, 1.9 mg/kg Q2W and had serial 521-gene ctDNA…
- Trial result
Non-small cell lung cancer
Relatlimab (LAG-3) + Nivolumab/Platinum Chemo Expands LAG-3⁺ Memory T Cells and Cuts Risk of Progression 45% in PD-L1 ≥1% Non-Sq NSCLC
In the Phase 2 RELATIVITY-104 study (NCT04623775), 1L metastatic NSCLC patients received nivolumab (PD-1 checkpoint inhibitor) + platinum-doublet chemotherapy with or without high-dose relatlimab (anti-LAG-3…
NCT04623775
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.